Acumen drops sabirnetug after Alzheimer's Phase 2 shows no benefit over placebo

Acumen Pharmaceuticals has stopped developing sabirnetug (ACU193), its antibody for early Alzheimer's disease, after the Phase 2 ALTITUDE-AD trial missed its primary endpoint. The topline results were announced on 30 October. The open-label extension is also being closed.

What the trial showed

ALTITUDE-AD was a randomised, double-blind, placebo-controlled study that enrolled 542 people with mild cognitive impairment or mild dementia due to Alzheimer's, at sites in the US, Canada, the EU and the UK. Participants received infusions every four weeks at 35 mg/kg or 50 mg/kg.

Get Tx Weekly every TuesdayThree-minute read. Free. One-click unsubscribe.

Neither dose separated from placebo on the primary measure, change in the integrated Alzheimer's Disease Rating Scale (iADRS) at 18 months. Key secondary endpoints, including the CDR-SB, were also missed. Amyloid plaque on PET scans did fall significantly at both doses at weeks 36 and 76, but that did not translate into a clinical benefit. Around 10% of treated participants had ARIA-E, the brain swelling seen with other amyloid antibodies.

Chief executive Daniel O'Connell said in the company's statement that Acumen was "disappointed the trial did not meet its primary endpoint". Acumen says further biomarker and imaging data are due in the coming weeks but are not expected to change the efficacy conclusion.

What happens to Acumen

Sabirnetug was Acumen's only clinical asset. BioSpace reports that shares fell about 80% to $0.44 in pre-market trading. The company plans cash conservation measures and is reviewing strategic options, including its Enhanced Brain Delivery programme, which builds on blood-brain barrier technology licensed from JCR Pharmaceuticals in July 2025. Neither the release nor BioSpace gives a cash runway or headcount figure.

The bigger picture

Sabirnetug was designed to bind soluble amyloid beta oligomers, which Acumen argued were an earlier and more toxic driver of disease than the plaques targeted by approved antibodies. BioSpace notes the data did not support that hypothesis. The readout lands just before the CTAD Alzheimer's conference, where Eisai and Biogen have said they will present new data, and in the same week that Ono stopped two endocannabinoid studies in psychiatry after Phase 2 failures. CNS remains one of the hardest places to turn biology into clinical benefit.

What it means for hiring

A single-asset company winding down its lead programme usually releases experienced Alzheimer's clinical operations, biomarker and medical people into the market. Well-funded CNS developers may find this a good window to hire.
Biomarker movement without clinical benefit raises the bar for neurodegeneration programmes. We'd expect sponsors to value clinical scientists and biostatisticians who can design trials around functional outcomes.
Companies holding brain-delivery platforms will need business development leaders who can position technology, not just a lead molecule, to partners.

Share Ask Harry about this →